Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 12/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | BMX | P51813 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2648695 | 1.00 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1ITKCDK2BMX | |
| SCHEMBL2648153 | 0.90 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1ITKCDK2BMX | |
| SCHEMBL2648156 | 0.90 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1ITKCDK2BMX | |
| SCHEMBL2648801 | 0.89 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1ITKCDK2MAPT | |
| SCHEMBL2648804 | 0.89 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1ITKCDK2MAPT | |
| SCHEMBL999295 | 0.87 | ITK (0.44) | ALDH1A1L3MBTL1ITKCDK2MAPT | |
| SCHEMBL999326 | 0.85 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1ITKCDK2BMX | |
| SCHEMBL1002441 | 0.85 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1ITKCDK2BMX | |
| SCHEMBL999288 | 0.83 | MAPT (0.46) | ALDH1A1L3MBTL1ITKCDK2BMX | |
| SCHEMBL2648177 | 0.83 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1ITKCDK2BMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582769-B2 | Dicycloalkyl urea glucokinase activators | NOVO NORDISK A/S (DK) | 2009-09-01 | — | — | US | disclosed |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| EP-1904466-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | GCK, GCKR, UCK2 | ALDH1A1 3782/4885L3MBTL1 3512/4885ITK 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.